Kelley Anne Saia, MD
Associate Professor, Obstetrics & Gynecology
Biography
Expertise includes: Treatment of substance use disorders in pregnancy and post-pregnancy, including opioid, alcohol, stimulant and marijuana use disorders; Trauma-informed care for pregnant persons with substance use disorder
Education
- University of Vermont, MD
- Georgetown University, BSN
- Hobart and William Smith Colleges, BA
Publications
- Published on 2/14/2024
Wachman EM, Saia K, Bressler J, Werler M, Carter G, Jones HE. Case Series of Individuals Treated with Naltrexone during Pregnancy for Opioid and/or Alcohol Use Disorder. J Addict Med. 2024 Feb 14. PMID: 38354121.
Read at: PubMed - Published on 10/1/2023
Harris M, Schiff DM, Saia K, Muftu S, Standish KR, Wachman EM. Academy of Breastfeeding Medicine Clinical Protocol #21: Breastfeeding in the Setting of Substance Use and Substance Use Disorder (Revised 2023). Breastfeed Med. 2023 Oct; 18(10):715-733. PMID: 37856658.
Read at: PubMed - Published on 9/20/2023
Deflorimonte C, Glissendorf V, Hofer J, Cai A, Iannella N, Boateng JO, Carter G, Saia KA, Jones HE, Wachman EM. National Provider Survey: Use of Naltrexone for Pregnant Individuals with Substance Use Disorders. J Addict Med. 2023 Sep 20. PMID: 37729010.
Read at: PubMed - Published on 9/20/2023
Deflorimonte C, Glissendorf V, Hofer J, Cai A, Iannella N, Boateng JO, Carter G, Saia KA, Jones HE, Wachman EM. National Provider Survey: Use of Naltrexone for Pregnant Individuals with Substance Use Disorders. J Addict Med. 2023 Nov-Dec 01; 17(6):736-738. PMID: 37934548.
Read at: PubMed - Published on 6/3/2023
Wanar A, Saia K, Field TA. Accelerated Fentanyl Metabolism During Pregnancy and Impact on Prenatal Drug Testing. Matern Child Health J. 2023 Nov; 27(11):1944-1948. PMID: 37269392.
Read at: PubMed - Published on 5/19/2023
Holland E, Gibbs L, Spence NZ, Young M, Werler MM, Guang Z, Saia K, Bateman BT, Achu R, Wachman EM. A comparison of postpartum opioid consumption and opioid discharge prescriptions among opioid-naïve patients and those with opioid use disorder. Am J Obstet Gynecol MFM. 2023 Aug; 5(8):101025. PMID: 37211090.
Read at: PubMed - Published on 1/9/2023
Laks J, Walley AY, Bagley SM, Barber CM, Gaeta JM, Neville LA, Peterkin AF, Rosenthal E, Saia KA, Weinstein ZM, Harris MTH. Developing a Women's Health track within addiction medicine fellowship: reflections and inspirations. Addict Sci Clin Pract. 2023 Jan 09; 18(1):3. PMID: 36617557.
Read at: PubMed - Published on 8/17/2022
Wanar A, Isley BC, Saia K, Field TA. False-positive Fentanyl Urine Detection after Initiation of Labetalol Treatment for Hypertension in Pregnancy: A Case Report. J Addict Med. 2022 Nov-Dec 01; 16(6):e417-e419. PMID: 35972891.
Read at: PubMed - Published on 8/17/2022
Wanar A, Saia K, Field T. Predictors of the Rate of Illicit Fentanyl Metabolism in a Cohort of Pregnant Individuals. J Addict Med. 2023 Jan-Feb 01; 17(1):85-88. PMID: 35972138.
Read at: PubMed - Published on 8/2/2022
Perry BN, Vais S, Boateng JO, Jain M, Wachman EM, Saia KA. Buprenorphine-naloxone Versus Buprenorphine for Treatment of Opioid Use Disorder in Pregnancy. J Addict Med. 2022 Nov-Dec 01; 16(6):e399-e404. PMID: 35916423.
Read at: PubMed
View 28 more publications: View full profile at BUMC